Proton pump inhibitor (PPI) use has been identifi ed as a risk factor for hip and vertebral fractures. Evidence supporting a relationship between PPI use and osteoporosis remains scant. Demonstrating that PPIs are associated with accelerated bone mineral density (BMD) loss would provide supportive evidence for a mechanism through which PPIs could increase fracture risk.
INTRODUCTION
Proton pump inhibitors, or PPIs, are among the most frequently prescribed medications in clinical practice, with 147 million prescriptions for PPIs being dispensed in the United States in 2010 ( 1 ) . Part of the reason for the widespread use of PPIs has been both their high effi cacy for the treatment and prevention of gastroesophageal refl ux disease and peptic ulcer disease ( 2 -4 ) , as well as their reputation for being well tolerated and unlikely to lead to long-term complications.
However, over the past decade, there have been an increasing number of studies that have linked the use of PPIs to increases in the risk for a variety of serious adverse events ( 5 -7 ) . Among the associations of highest concern has been the possible link between the long-term use of PPIs and the development of osteoporosisrelated fractures, particularly those of the hip (8 -15) . Th is association has been primarily detected through the retrospective analysis of pre-existing data, and the strengths of the associations have ranged considerably from study to study. To date, there are no studies using data that were prospectively collected to evaluate the association between PPI use and fracture. Furthermore, the mechanism through which PPI use could increase the risk of fracture has yet to be elucidated ( 16, 17 ) . In spite of these limitations, the US Food and Drug Administration has issued a black-box warning advising that PPI use may increase the risk of subsequent fracture ( 18 ) .
If the association between PPIs and fracture is indeed causal, then one would expect to also see an eff ect of PPIs on the intermediate pathways that predispose to fracture. In particular, determining that PPI use is associated with the development of low bone mineral density (BMD) from which the diagnosis of osteoporosis could be made, or with accelerated loss of longitudinally assessed BMD, would provide tangible support for the causality of the PPI -fracture association. Previous studies, which have analyzed the association between PPI use and BMD, have yielded confl icting results ( 8, 19, 20 ) ; and thus, the true relationship between PPIs and changes in BMD remains poorly characterized. Th erefore, we sought to use a large population-based cohort to determine the relationships between prior PPI use and BMD at the time of enrollment and, using longitudinal assessments of BMD, to determine whether those with chronic PPI use have a diff erent rate of BMD change than non-PPI-treated people.
METHODS

Description of population studied
Th is study was performed using data collected as part of the Canadian Multicentre Osteoporosis Study (CaMos). CaMos consists of a population-based stratifi ed random sample of the Canadian population. Between 1995 and 1997, a combination of random digit dialing and random household member selection was used to identify potential subjects aged 25 years or older who lived within 50 km of one of nine urban Canadian recruitment centers (Vancouver, Calgary, Saskatoon, Toronto, Hamilton, Kingston, Quebec City, Halifax, and St John ' s) ( 21 ) .
All subjects who agreed to enroll underwent a comprehensive in-person interviewer-administered questionnaire (IAQ) at baseline (y0) designed to gather information on medical history and numerous risk factors for osteoporosis and fracture, a complete dietary assessment focusing on intakes of calcium and Vitamin D, as well as socio-demographic information and anthropomorphic measurements. BMD assessment was performed using dual X-ray absorptiometry (DXA) scanning on all enrolled subjects. Standardization between DXA scanners was assured by use of a common phantom that was circulated to each of the centers. Adequacy of the cross-calibration and quality control procedures was evaluated by performing all analyses with and without adjustment for recruiting center and confi rming that results were unaff ected. BMD measurements were obtained at the lumbar spine (L1 -L4), femoral neck, and total hip. Medication use was assessed by asking subjects to bring into the study center any actively used medications. Subjects were asked about osteoprotective medications and glucocorticoids by name. Subjects were asked to show the interviewers all other medications which they took regularly. Th e dose and indication for these medications were not specifi cally recorded.
At year 5 (y5) and year 10 (y10) following initial enrollment, the IAQ was repeated, medication use was again captured, and BMD was remeasured. Duration of medication use was not specifi cally collected; dose and strength of medication was recorded only at the initial visit. A full description of the methodology and survey design employed in CaMos has been previously published ( 21 ) .
Description of analyses
We performed a cross-sectional analysis to determine the relationship between PPI use at y0 and BMD at each anatomic site. We then performed longitudinal analyses of the relationship between PPI use and the change in BMD at each anatomic site between y0 and y5, between y0 and y10, and between y5 and y10. In the cross-sectional analyses, a subject was considered to be a PPI user if PPI use was reported in the y0 IAQ. In the longitudinal analyses, a subject was considered to be a continuous PPI user if PPI use was reported at all time points included in the analysis. We also evaluated the eff ect of current PPI use (use at year 5 for the y0 -y5 analysis and use at year 10 for the y0 -y10 analysis).
We used multivariate general linear regression to control for the eff ects of multiple potential confounders, including age, sex, age -sex interactions, body mass index, personal history of minimal trauma fracture, family history of minimal trauma fracture, presence of rheumatoid arthritis, infl ammatory bowel disease, chronic liver disease, chronic kidney disease, thyroid disease, current smoking, heavy alcohol use (defi ned as 14 drinks per week or greater), history of falls, and study center. We also controlled for the use of concomitant medications that may infl uence BMD, including systemic glucocorticoids, thiazide diuretics, β -blockers, nitrates, anti-epileptics, selective serotonin receptor inhibitors, tamoxifen, and osteoprotective medications (including menopausal hormone therapy, bisphosphonates, and selective estrogen receptor modulators). A participant was considered to have a potential confounding medical condition if the presence of that condition was recorded at any time point. A subject was considered to be exposed to a confounding medication if there was recorded use at the most recent time point, refl ective of ongoing use. We also controlled for total calcium intake and Vitamin D intake, with subjects considered to have adequate use of calcium and Vitamin D if their reported daily intake from both diet and supplementary sources met or exceeded 1,200 mg calcium and / or 400 IU of Vitamin D. Interaction terms for PPI use and bisphosphonate use were also included in the model to test for the reported possible negative interaction between PPIs and bisphosphonates ( 22 ) . No stepwise selection techniques were utilized for entry of covariates into any of the models, and covariates were considered to be statistically signifi cant if the P -value was < 0.05. All statistical analyses were performed using Statistica 10 (Statsoft Inc., Tulsa, OK).
RESULTS
Overall, 9,423 subjects were enrolled in the original CaMos cohort, of whom 8,340 completed the initial IAQ and underwent initial BMD assessments. In all, 6,458 participants (77 % ) underwent repeat assessments of the full IAQ and measurement of BMD at 5 years, and 4,512 (55 % ) completed the full 10 years of follow-up. Description of the participants included in the baseline analyses and in the longitudinal analyses is summarized in Table 1 . In the baseline cross-sectional analyses, 228 (2.7 % ) subjects reported using PPIs. PPI use increased to 7.6 % at year 5 and 11.5 % at year 10. Continuous use of PPI at all time points was limited to 0.9 % of the cohort.
Baseline comparisons of PPI users and non-users are shown in Figure 1 and Table 2 . Users of PPIs had signifi cantly lower unadjusted BMD at each of the measurement sites. PPI users were also signifi cantly older, had a higher mean BMI, greater intakes of calcium and Vitamin D, and reported a slightly higher rate of prior fracture than non-PPI users. PPI users were also much more likely to have many of the concurrent medical conditions, and were more likely to be using many of the medications, including bisphosphonates, glucocorticoids, selective serotonin receptor inhibitors, thiazides, nitrates, and β -blockers.
Aft er adjusting for multiple confounders, PPI use was associated with lower baseline BMD at both the total hip ( − 0.019 ± 0.008 g / cm 2 , P = 0.028) and the femoral neck ( − 0.022 ± 0.007 g / cm 2 , P = 0.002), but not at the lumbar spine ( − 0.014 ± 0.011 g / cm 2 , P = 0.179) ( Table 3 ). When users of osteoprotective medications and glucocorticoids were excluded, PPI use was again associated with lower adjusted baseline BMD at the femoral neck ( − 0.026 ± 0.008 g / cm 2 , P = 0.002) and total hip ( − 0.026 ± 0.010 g / cm 2 , P = 0.008). Limiting the analysis to subjects over the age of 50 years did not signifi cantly aff ect the parameter estimates for PPI use (total hip: − 0.021 ± 0.010 g / cm 2 , P = 0.028, femoral neck: − 0.025 ± 0.008 g / cm 2 , P = 0.002). Aft er adjustment for potential confounders, the regression models did not demonstrate a signifi cant association between continuous PPI use and the rate of change in BMD at any of the measurement sites between y0 and y5, between y0 and y10, or between y5 and y10 ( Table 4 ) . Th e lack of an association between PPI use and change in BMD remained when PPI use was defi ned as being current at the time of the most recent BMD assessment. Th ere were also no significant changes in BMD attributable to PPI use in analyses restricted to subjects over age 50 years and to those not using glucocorticoids or osteoprotective medications. Th e use of bisphosphonates and menopausal hormone therapy was uniformly associated with increasing BMD. BMD gains of lower magnitude were also associated with the use of thiazide diuretics, whereas glucocorticoid use was oft en predictive of BMD loss. Interactions between PPI and bisphosphonate use were not detected in any of the longitudinal analyses.
DISCUSSION
In this large, population-based, prospective assessment of BMD, the use of PPIs was associated with lower covariate-adjusted BMD at baseline at the total hip and femoral neck. However, continuous PPI use for both 5 and 10 years was not associated with a signifi cant negative infl uence on the change in BMD over time.
Th ese are a number of potential explanations for the apparently discordant fi ndings of lower BMD at y0 among PPI users and the lack of further PPI-associated decline in BMD in up to 10 years of follow-up. As this was not an experimental study, there may have been signifi cant diff erences in the cohort among persons who reported PPI use at baseline, and those who were non-users. It is possible that PPI users had unmeasured variables which predisposed to low BMD, and that these factors were not completely accounted for through the regression analysis. While there are no obvious reasons why low BMD should directly promote higher rates of PPI use, low BMD may be a marker for other comorbidities that may predispose participants to PPI use. Previous studies have suggested that PPI use is much more common among subjects with indicators of frailty, including the use of multiple distinct medications, higher levels of overall comorbidity, and poor mobility ( 23 ) . Th ese markers of frailty may also be associated with low BMD and increased fracture ( 24 ) . Although we did make attempts to control for concomitant medical conditions and drug use known to aff ect BMD, we could not control for the severity of these diseases, nor could we control the duration and / or dose of medication usage. If individuals with low BMD, who are also presumably at higher fracture risk, are more likely to be started on PPIs, then this may conceivably explain the fi ndings of other studies that report an association between PPI use and fracture. As is suggested in Table 2 , PPI users were signifi cantly more likely to use other medications known to negatively infl uence BMD, and were also more likely to have rheumatoid arthritis, COPD , thyroid disease, chronic renal disease, or infl ammatory bowel disease. In contrast, as only 0.9 % of the sample used PPIs continuously over the 10 years of the study, we may not have had suffi cient power to detect a clinically signifi cant change in BMD associated with PPI use. However, even in the y5 -y10 analysis, during which time 4.3 % of subjects were continuous PPI users, our fi ndings do not support a clinically signifi cant eff ect of PPI use on the rate of BMD change (e.g., mean femoral neck loss − 0.3 % over 5 years with the lower limit of the 95 % confi dence interval − 1.4 % ). Another possible explanation is that the majority of any negative eff ect on BMD occurs relatively soon aft er initiation of PPI therapy, and thus the failure to detect further changes in the BMD 
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Further supporting our fi nding is the lack of a defi nitive physiologic mechanism through which PPI use would negatively aff ect BMD. It had long been assumed that PPIs decrease the fractional absorption of calcium by decreasing the solubility of ingested calcium salts ( 26, 27 ) . Over time, this might promote secondary hyperparathyroidism and osteoclast activation, which in turn can promote increased bone turnover and accelerated BMD decline ( 28 ) . Studies in animal models have also suggested that PPIinduced hypergastrinemia may also promote hypertrophy of the parathyroid glands ( 29, 30 ) . While PPIs have been shown to cause decreased bone mass in adolescent rats ( 31 ) , there have yet to be any human studies which have demonstrated that PPI use is associated with signifi cant bone loss ( 32 ) . However, the only studies that have demonstrated decreased calcium absorption among PPI users have been those that specifi cally assessed absorption of supplemental calcium carbonate in fasting individuals ( 26, 27 ) . In all other scenarios using diff erent formulations of supplemental calcium or calcium ingestion associated with meals, no eff ects of PPIs on calcium absorption have been shown ( 33 -35 ) . It remains possible, nevertheless, that very marginal decrements in net calcium absorption may, over long periods of time, induce a large enough net calcium loss to cause clinically meaningful reductions in BMD ( 36 ) . In other studies, PPIs have been shown, in vitro , to directly inhibit osteoclast function through a blockade of the vacuolar proton pump located on the osteoclast ruffl ed border, and therefore may prevent bone resorption and potentially actually increase BMD ( 37 ) . Further to this point, people with congenital osteopetrosis, who do not express the vacuolar proton pump, develop marked cortical thickening and increased BMD, yet have a signifi cantly increased risk of fracture ( 38 ) . Nevertheless, there is currently no evidence of a direct eff ect of PPIs on osteoclast activity in vivo . Th erefore, while there are putative lines of evidence to suggest that chronic PPI use may aff ect bone metabolism, the precise mechanism through which PPIs may aff ect bone turnover and BMD remains unexplained.
Th is study has several notable strengths. Other studies of the relationship between PPI use and BMD have been performed in restricted populations. Th e SOF and MrOS cohorts were not drawn from population-based data sources, and were restricted in enrollment to women or men over the age of 65 years; the previous study using the Manitoba DXA registry was based on a population referred for BMD testing. CaMos enrolled randomly over time among those who continued to use PPIs was due to a ceiling eff ect. Some of the prior research studying the relationship between PPI use and fractures detected an increase in fracture risk early in the course of therapy with no further increases over time, while others have shown greater increases in risk with longer durations of use ( 12, 25 ) .
Th ough there have been many papers discussing the possible relationship between PPI use and osteoporosis-related fracture, there is a relative paucity of the published research concerning the association of PPI use with the development of osteoporosis based on DXA-measured BMD, the structural defect which most commonly predisposes to the development of fragility fracture. , P = 0.05), whereas the total hip diff erence in BMD at baseline in SOF was not signifi cant (PPI user vs. non-user, 0.729 vs. 0.736 g / cm 2 , P > 0.2). Gray et al. ( 20 ) analyzed data from the Women ' s Health Initiative and determined that both PPI users and non-users had an increase in BMD at the total hip from baseline to year 3, but the annualized rate in BMD increase was signifi cantly lower among PPI users than non-PPI users (0.21 % per year vs. 0.45 % per year, P = 0.05). Finally, a retrospective analysis of a large clinical DXA registry in Manitoba, Canada, found no relationship between BMD measurement at the lumbar spine or total hip and cumulative PPI exposure in the 5 years before BMD testing ( 19 ) ; furthermore, PPI use was not associated with a more rapid rate of BMD decline among subjects who received a follow-up DXA 1 -3 years following the initial test.
Taking the results of these previous studies and the current analysis into account, the weight of the evidence suggests an absence of an association between PPI use and BMD change over time. Th is further increases the likelihood that the reported association between PPI and fractures may represent baseline diff erences in fracture risk between PPI users and non-users, which are unrelated to the actual use of the medication. Abbreviations: BMD, bone mineral density; SERMs, selective estrogen receptor modulators; SSRIs, selective serotonin receptor inhibitors. Linear regression models controlled for the following variables at year 0: age (grouped in 10 year intervals), sex, age -sex interactions, body mass index, calcium intake, Vitamin D intake; report of: rheumatoid arthritis, infl ammatory bowel disease, chronic kidney disease, chronic liver disease, hyper-and hypothyroidism; and use of: bisphosphonates, hormone replacement therapy, SERMs, calcitonin, tamoxifen, β -blockers, nitrates, SSRIs, thiazide diuretics, anti-epileptics; current smoking, and heavy alcohol use. Results are expressed as the mean difference in year 0 BMD attributable to PPI use. Shaded results are statistically signifi cant ( P < 0.05).
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Targownik et al. Abbreviations: BMD, bone mineral density; BMI, body mass index; GC, glucocorticoid; HT, hormone therapy; SERMs, selective estrogen receptor modulators; SSRIs, selective serotonin receptor inhibitors.
Linear regression models controlled for: age (grouped in 10-year intervals), sex, BMI at baseline, change in BMI, calcium intake, Vitamin D intake, report of: rheumatoid arthritis, infl ammatory bowel disease, chronic kidney disease, chronic liver disease, hyper-and hypothyroidism, and use of: bisphosphonates, hormone replacement therapy, SERMs, calcitonin, tamoxifen, β -blockers, nitrates, SSRIs, thiazide diuretics, anti-epileptics, smoking, and heavy alcohol use. Results are expressed as the mean percentage change from the baseline BMD. Bolded results are statistically signifi cant (
sampled participants from across the age spectrum, and therefore the results obtained from this study may be more generalizable to the general population. Th e study population in CaMos had up to 10 years of follow-up, allowing for detection of small changes that may accrue over time. CaMos also captures nearly all of the factors that may potentially infl uence BMD, making it less likely that there was omission of signifi cant confounders, which might importantly bias the results. Th is analysis also had limitations that are worthy of mention. Although attempts were made to capture a study population representative of the Canadian population at large, the potential for subject recruitment and retention bias still exists. However, previous analyses have suggested that the composition of the non-responding population was similar to those who have enrolled, and there is little reason to believe that PPI use / non-use would have infl uenced the decision to enroll or drop-out, making it an unlikely source of bias ( 21 ) . Second, as data on the past medical history, diet, smoking, and alcohol use was based on self-report, there is the potential for misreporting biases. It is also possible that, as PPI use was only queried at specifi c time points, subjects who reported PPI use at the y5 or y10 were using PPIs only recently, or perhaps were using them discontinuously, mitigating against any deleterious eff ects on BMD. Furthermore, our inability to determine whether or not PPIs were being utilized in between survey points may potentially lead to misclassifi cation, which may bias our results toward minimizing the presence of a true drug eff ect. Further prospective research may be required to better delineate the relationship between the timing and duration of PPI use on BMD. Once again, any misclassifi cation is unlikely to be related to PPI use, and thus any bias would likely be toward the null, i.e., a lack of eff ect. Finally, as subjects were aware that they were part of a prospective cohort studying BMD-related outcomes, they may have adopted behaviors or made health-care choices that they would not have made if they were not participating in a study on osteoporosis. Participants in CaMos have higher rates of osteoprotective medication use than in the general population, and also report higher mean intakes of calcium and Vitamin D. However, none of these choices should infl uence the direct eff ect of PPIs on BMD, an objectively measured outcome. Th us, although we believe that some limitations are present, they do not greatly aff ect the validity of our fi ndings.
In conclusion, PPI use is associated with lower baseline femoral neck and total hip BMD values, but there does not appear to be an increased rate of BMD loss on subsequent measurements extending out to 10 years. Th ese fi ndings provide support for the view that PPI use does not have a signifi cant eff ect on bone mineral loss, and that the increase in PPI-associated fracture risk described in other studies may be due to residual confounding, or alternatively, a BMD-independent cause for fracture. Further studies to better delineate or rule out potential mechanisms through which PPIs may aff ect bone strength or fracture risk are needed to provide additional evidence about whether PPIs truly have a clinically meaningful, direct relationship with bone health.
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